

Author Index

Absi L, 214
 Ackerley CA, 271
 Ager J, 618
 Agid Y, 257
 Albanese A, 362
 Alexander CJ, 35
 Alkadhri H, 384
 Almer G, 176
 Alpéravit A, 411
 Amer G, 263
 Amyes ER, 253
 Anand I, 117
 Andermann F, 770
 Andersen P, 643
 Andrade DM, 271
 Antel SB, 770
 Antoine J-C, 214
 Antonini A, 155
 Antozzi C, 106
 Arai H, 276
 Arai H, 544
 Archelos JJ, 135
 Archer SA, 320
 Arimura K, 544
 Armelle Cheval M, 607
 Arnold DL, 770
 Arnold SE, 165
 Asmus F, 121
 Averbeck B, 7
 Bagli M, 819
 Baiget M, 130
 Ball WS, 401
 Ballaban-Gil K, 328
 Baloh RW, 800
 Banin E, 278
 Baram TZ, 304
 Barker PB, 423
 Barkow K, 819
 Barnes LF, 761
 Barthélémy C, 607
 Basu S, 114
 Baulac M, 786
 Baulac S, 786
 Baumgärtner U, 493
 Beal MF, 561
 Beaudry P, 257
 Becker G, 405
 Benaim E, 222
 Benaroch EE, 146
 Benecke R, 536
 Bennett D, 202
 Bentivoglio AR, 362
 Berg AT, 659
 Berg D, 121
 Berg D, 405
 Berghold A, 135
 Berkovic SF, 45
 Bernasconi A, 770
 Bernasconi N, 770
 Berry-Kravis E, 98
 Bertram L, 114
 Bertram M, 121
 Bezman L, 186
 Bezman L, 512
 Bhidayasiri R, 24
 Bird ED, 29
 Bird T, 486
 Bird TD, 144
 Bird TD, 817
 Birnbaum G, 135
 Bisch A, 793
 Black JT, 396
 Blacker D, 114
 Blamire AM, 590
 Blandini F, 525
 Bock N, 393
 Boecker H, 813
 Bokil HS, 24
 Booth G, 98
 Bottos C, 257
 Bowman LC, 222
 Bowser R, 249
 Bradley JL, 590
 Brandel J-P, 257
 Breitner JCS, 418
 Bresolin N, 137
 Brice A, 117
 Brice A, 786
 Briellmann RS, 45
 Briolotti V, 267
 Broderick J, 736
 Broe GA, 125
 Brooks WS, 125
 Brott T, 736
 Brown GK, 805
 Brown H, 808
 Brown RH, 130
 Brown RM, 805
 Bruce J, 165
 Brück W, 793
 Brunson KL, 304
 Buerger K, 545
 Buldyrev I, 808
 Burstein AH, 706
 Bushara KO, 540
 Bushby KMD, 443
 Bynevelt M, 477
 Byrnes ML, 320
 Calamante F, 477
 Calne DB, 298
 Camdessané J-P, 214
 Camu W, 267
 Camuzat A, 117
 Capone A, 518
 Cappai R, 125
 Carnero C, 263
 Carrara F, 106
 Cassetta E, 362
 Castelot Konkiewitz E, 813
 Cavanagh J, 313
 Ceballos-Baumann A, 121
 Ceballos-Baumann AO, 813
 Cecil KM, 401
 Chan D, 433
 Chan E, 271
 Chapin J, 776
 Chatterjee S, 345
 Chelimsky TC, 453
 Chémali KR, 453
 Chen C, 176
 Chew N-K, 810
 Chiba H, 544
 Chinney PF, 443
 Cho HS, 697
 Chong H-T, 810
 Chong WK, 805
 Chow T, 355
 Chu Y, 202
 Chua, K-B, 810
 Chuck G, 401
 Chugani DC, 618
 Chugani HT, 618
 Cipolotti L, 433
 Clark CM, 165
 Classen J, 536
 Clatterbuck RE, 682
 Clavelou P, 267
 Clayton D, 665
 Cochran EJ, 202
 Cohen J, 328
 Collins DL, 770
 Comi G, 290
 Comi G, 415
 Comi GP, 137
 Conant K, 230
 Conforto A, 345
 Connally A, 477
 Conrad B, 813
 Conway JE, 682
 Cooper JM, 590
 Corbett D, 230
 Corona P, 106
 Costa AF, 529
 Cotton RGH, 125
 Cox TC, 477
 Crilley JG, 590
 Crino PB, 67
 Croen LA, 597
 Cross AH, 396
 Crum WR, 433
 Crystal A, 114
 Cullen M, 443
 Cummings JL, 280
 Cummings JL, 355
 Cunningham JM, 222
 Cupples LA, 29
 Cutting LE, 279
 Dalakas MC, 532
 Dalmau JO, 141
 Damasio A, 53
 Dambrosia JM, 597
 Daniel S, 665
 Daniels G, 384
 Darin N, 377
 Davies M, 470
 Davies P, 545
 Davis MB, 362
 De Jonghe P, 245
 De La Fuente-Fernandez R, 298
 De Pasqua V, 668
 De Silva R, 665
 DeGrauw TJ, 401
 DeKosky ST, 202
 Del Bigio MR, 727
 Del Bo R, 137
 Del Favero J, 245
 DeLong MR, 142
 Deng A, 114
 Devinsky O, 575
 Dhawan V, 155
 Diaz J, 607
 Dichgans M, 121
 Dickens BF, 597
 Dicker E, 328
 D'Incerti L, 106
 Dittmann R, 585
 Dixon P, 665
 Dixon PH, 362
 Dowling P, 776
 Dubau F, 770
 Ducimetière P, 411
 Dufouil C, 411
 Dugan LL, 627
 Durner M, 328
 Dürr A, 117
 Dütsch M, 575
 Ebersberger A, 7
 Eghbal-Ahmadi M, 304
 Eidelberg D, 155
 Elpeleg O, 195
 Escolar DM, 706
 Esiri MM, 253
 Espinosa G, 408
 Evans JPM, 477
 Evgrafov O, 245
 Fagan SC, 736
 Fardeau M, 607
 Fawcett PRW, 443
 Feingold J, 786
 Feinstein DL, 276
 Fernandez M, 486
 Ferrar MD, 753

January issue, pp 1-140; February issue, pp 141-280; March issue, pp 281-420; April issue, pp 421-554; May issue, pp 555-690; June issue, pp 691-840.

Author Index

Absi L, 214
 Ackerley CA, 271
 Ager J, 618
 Agid Y, 257
 Albanese A, 362
 Alexander CJ, 35
 Alkadhri H, 384
 Almer G, 176
 Alpéravit A, 411
 Amer G, 263
 Amyes ER, 253
 Anand I, 117
 Andermann F, 770
 Andersen P, 643
 Andrade DM, 271
 Antel SB, 770
 Antoine J-C, 214
 Antonini A, 155
 Antozzi C, 106
 Arai H, 276
 Arai H, 544
 Archelos JJ, 135
 Archer SA, 320
 Arimura K, 544
 Armelle Cheval M, 607
 Arnold DL, 770
 Arnold SE, 165
 Asmus F, 121
 Averbeck B, 7
 Bagli M, 819
 Baiget M, 130
 Ball WS, 401
 Ballaban-Gil K, 328
 Baloh RW, 800
 Banin E, 278
 Baram TZ, 304
 Barker PB, 423
 Barkow K, 819
 Barnes LF, 761
 Barthélémy C, 607
 Basu S, 114
 Baulac M, 786
 Baulac S, 786
 Baumgärtner U, 493
 Beal MF, 561
 Beaudry P, 257
 Becker G, 405
 Benaim E, 222
 Benaroch EE, 146
 Benecke R, 536
 Bennett D, 202
 Bentivoglio AR, 362
 Berg AT, 659
 Berg D, 121
 Berg D, 405
 Berghold A, 135
 Berkovic SF, 45
 Bernasconi A, 770
 Bernasconi N, 770
 Berry-Kravis E, 98
 Bertram L, 114
 Bertram M, 121
 Bezman L, 186
 Bezman L, 512
 Bhidayasiri R, 24
 Bird ED, 29
 Bird T, 486
 Bird TD, 144
 Bird TD, 817
 Birnbaum G, 135
 Bisch A, 793
 Black JT, 396
 Blacker D, 114
 Blamire AM, 590
 Blandini F, 525
 Bock N, 393
 Boecker H, 813
 Bokil HS, 24
 Booth G, 98
 Bottos C, 257
 Bowman LC, 222
 Bowser R, 249
 Bradley JL, 590
 Brandel J-P, 257
 Breitner JCS, 418
 Bresolin N, 137
 Brice A, 117
 Brice A, 786
 Briellmann RS, 45
 Briolotti V, 267
 Broderick J, 736
 Broe GA, 125
 Brooks WS, 125
 Brott T, 736
 Brown GK, 805
 Brown H, 808
 Brown RH, 130
 Brown RM, 805
 Bruce J, 165
 Brück W, 793
 Brunson KL, 304
 Buerger K, 545
 Buldyrev I, 808
 Burstein AH, 706
 Bushara KO, 540
 Bushby KMD, 443
 Bynevelt M, 477
 Byrnes ML, 320
 Calamante F, 477
 Calne DB, 298
 Camdessané J-P, 214
 Camu W, 267
 Camuzat A, 117
 Capone A, 518
 Cappai R, 125
 Carnero C, 263
 Carrara F, 106
 Cassetta E, 362
 Castelot Konkiewitz E, 813
 Cavanagh J, 313
 Ceballos-Baumann A, 121
 Ceballos-Baumann AO, 813
 Cecil KM, 401
 Chan D, 433
 Chan E, 271
 Chapin J, 776
 Chatterjee S, 345
 Chelimsky TC, 453
 Chémali KR, 453
 Chen C, 176
 Chew N-K, 810
 Chiba H, 544
 Chinney PF, 443
 Cho HS, 697
 Chong H-T, 810
 Chong WK, 805
 Chow T, 355
 Chu Y, 202
 Chua, K-B, 810
 Chuck G, 401
 Chugani DC, 618
 Chugani HT, 618
 Cipolotti L, 433
 Clark CM, 165
 Classen J, 536
 Clatterbuck RE, 682
 Clavelou P, 267
 Clayton D, 665
 Cochran EJ, 202
 Cohen J, 328
 Collins DL, 770
 Comi G, 290
 Comi G, 415
 Comi GP, 137
 Conant K, 230
 Conforto A, 345
 Connally A, 477
 Conrad B, 813
 Conway JE, 682
 Cooper JM, 590
 Corbett D, 230
 Corona P, 106
 Costa AF, 529
 Cotton RGH, 125
 Cox TC, 477
 Crilley JG, 590
 Crino PB, 67
 Croen LA, 597
 Cross AH, 396
 Crum WR, 433
 Crystal A, 114
 Cullen M, 443
 Cummings JL, 280
 Cummings JL, 355
 Cunningham JM, 222
 Cupples LA, 29
 Cutting LE, 279
 Dalakas MC, 532
 Dalmau JO, 141
 Damasio A, 53
 Dambrosia JM, 597
 Daniel S, 665
 Daniels G, 384
 Darin N, 377
 Davies M, 470
 Davies P, 545
 Davis MB, 362
 De Jonghe P, 245
 De La Fuente-Fernandez R, 298
 De Pasqua V, 668
 De Silva R, 665
 DeGrauw TJ, 401
 DeKosky ST, 202
 Del Bigio MR, 727
 Del Bo R, 137
 Del Favero J, 245
 DeLong MR, 142
 Deng A, 114
 Devinsky O, 575
 Dhawan V, 155
 Diaz J, 607
 Dichgans M, 121
 Dickens BF, 597
 Dicker E, 328
 D'Incerti L, 106
 Dittmann R, 585
 Dixon P, 665
 Dixon PH, 362
 Dowling P, 776
 Dubau F, 770
 Ducimetière P, 411
 Dufouil C, 411
 Dugan LL, 627
 Durner M, 328
 Dürr A, 117
 Dütsch M, 575
 Ebersberger A, 7
 Eghbal-Ahmadi M, 304
 Eidelberg D, 155
 Elpeleg O, 195
 Escolar DM, 706
 Esiri MM, 253
 Espinosa G, 408
 Evans JPM, 477
 Evgrafov O, 245
 Fagan SC, 736
 Fardeau M, 607
 Fawcett PRW, 443
 Feingold J, 786
 Feinstein DL, 276
 Fernandez M, 486
 Ferrar MD, 753

January issue, pp 1-140; February issue, pp 141-280; March issue, pp 281-420; April issue, pp 421-554; May issue, pp 555-690; June issue, pp 691-840.

Ferraris A, 362
 Ferriero DM, 820
 Fiebach JB, 460
 Filippi M, 290
 Filippi M, 415
 Fischbeck KH, 706
 Fitzek C, 493
 Fitzek S, 493
 Fitzsimons RB, 753
 Flowers JM, 643
 Font J, 408
 Ford B, 761
 Forss N, 90
 Foster NL, 416
 Fotheringham J, 727
 Fox NC, 433
 Frachon P, 607
 Francis MJ, 405
 Frants RR, 753
 Frey KA, 285
 Frey KA, 416
 Friend JC, 29
 Frontali M, 362
 Frucht S, 761
 Fuchs S, 121
 Fujigasaki H, 117
 Fujino H, 685
 Fukuda M, 155
 Fulthorpe JJ, 443
 Fursdon Davis CJ, 253

Gabreëls-Festen A, 797
 Gadian DG, 477
 Gailloud P, 682
 Galasko D, 165
 Gallano P, 130
 Gallardo E, 130
 Ganstedt U, 672
 Garakian J, 355
 García T, 263
 Gasser T, 121
 Genin E, 786
 Ghaemi M, 367
 Ghez C, 155
 Ghilardi MF, 155
 Gibson GJ, 443
 Gieffers J, 585
 Giger JD, 727
 Go R, 114
 Goadsby PJ, 4
 Goebel SU, 540
 Goh K-J, 810
 Goldfarb LG, 540
 Goldmann C, 636
 Gómez-Tortosa E, 29
 Gonzalez G, 650
 Goodridge DM, 336
 Gorodeski R, 453
 Goutieres F, 607
 Grabowski TJ, 697
 Graf W, 486
 Graham E, 665
 Greenamyre JT, 525
 Greenberg DA, 328
 Greenberg SM, 697
 Grether JK, 597

Griesmann GE, 146
 Griffin JW, 694
 Gropman AL, 706
 Grossman M, 165
 Gross-Tsur V, 278
 Grotta JC, 736
 Guégan C, 176
 Guénette S, 114
 Gusella JF, 29

Haan J, 753
 Haass A, 585
 Hacke W, 460
 Hadley DW, 706
 Haley EC, 736
 Hall SM, 470
 Hallett M, 540
 Halliday G, 313
 Hallupp M, 125
 Hamada C, 138
 Hamed S, 706
 Hammerstad J, 155
 Hampel H, 545
 Hand CK, 267
 Hanefeld F, 585
 Hansen RL, 597
 Harden C, 328
 Hart PE, 590
 Hartung H-P, 135
 Hasegawa M, 501
 Hashemi-Nejad A, 521
 Hashimoto T, 242
 Hayashi S, 14
 Hayashi S, 712
 Hays AP, 176
 Hays AP, 249
 Heiland S, 460
 Heinrich H, 393
 Heiss W-D, 367
 Helton KJ, 222
 Heneka MT, 276
 Hennig J, 518
 Hergersberg M, 384
 Herholz K, 367
 Herman A, 786
 Hertz S, 328
 Hess K, 384
 Hetta J, 136
 Heun R, 819
 Heywood P, 753
 Higuchi I, 544
 Higuchi S, 276
 Higuchi S, 544
 Hilker R, 367
 Hilz MJ, 575
 Hirai H, 544
 Hirata K, 712
 Hirsch E, 786
 Hoffman EP, 706
 Hohlfeld R, 281
 Holden J, 650
 Holden JE, 298
 Holme E, 377
 Holmes SE, 117
 Holopainen IE, 110
 Holtkamp M, 260

Honorat J, 214
 Hooper DC, 139
 Hopf HC, 493
 Horstink MWIM, 797
 Horwitz EM, 222
 Houlden H, 521
 Hua Y, 67
 Hudson P, 443
 Hughes S, 253
 Hyman BT, 114
 Hyman BT, 808

Ialongo T, 362
 Ianzano L, 271
 Ikeda S-I, 242
 Ikeda S-I, 546
 Illa I, 130
 Imbimbo BP, 416
 Iwaki H, 544
 Iwatsubo T, 501
 Izquierdo G, 529
 Izumi Y, 242

Jackson C, 736
 Jackson GD, 45
 Jacobson KM, 800
 Jakobs C, 401
 Jamieson S, 443
 Jamot L, 117
 Janisse JJ, 618
 Jansen O, 460
 Jardine PE, 753
 Jelliffe LL, 597
 Jen IC, 800
 Jivan S, 298
 Johnson AL, 336
 Johnson MA, 443
 Johnson RT, 1
 Johnson RT, 820
 Johnston JB, 230
 Johnston JB, 650
 Jones J, 114
 Juhász C, 618
 Jung HH, 384

Kabus C, 121
 Kaipur J, 820
 Kaji R, 138
 Kamarulzaman A, 810
 Kamijo M, 712
 Kang H, 328
 Kapoor R, 470
 Karjalainen T, 90
 Karpati G, 693
 Kasama T, 712
 Kass NE, 512
 Katai S, 242
 Kaup FJ, 636
 Keddache MA, 328
 Keeney D, 114
 Khan N, 304
 Khan N, 665
 Khoris J, 267
 Ki C-S, 817
 Kilbourn MR, 416
 Kim DK, 817

Kim HJ, 817
 Kim JI, 24
 Kim J-W, 817
 Kim K-K, 146
 Kimura M, 276
 King RHM, 521
 Kirkham FJ, 477
 Kis B, 367
 Klein C, 367
 Klepper J, 685
 Klotz I, 328
 Klotz K, 585
 Kneifel S, 384
 Kockler M, 819
 Koeppe RA, 416
 Koga M, 712
 Kohnken R, 545
 Kokkonen H, 110
 Kokubo Y, 501
 Koller W, 155
 Kollias S, 384
 Kölisch H, 819
 Kopp N, 214
 Koprowski H, 139
 Kordower JH, 202
 Korpi ER, 110
 Kors EE, 753
 Kothari R, 736
 Koyanagi A, 685
 Krämer M, 636
 Krametter D, 135
 Krance R, 222
 Kremer BPH, 797
 Kril JJ, 125
 Kruse N, 405
 Kryzer TJ, 146
 Kuhl DE, 416
 Kuhlmann T, 793
 Kunesch E, 536
 Kunjapani SR, 810
 Kuzuhara S, 501
 Kwok JBJ, 125

Labar DR, 328
 Ladkani D, 415
 Larn, S-K, 810
 Lamantea E, 106
 Landreth GE, 276
 Lang A, 155
 Laplanche JL, 257
 Lasa A, 130
 Lassmann H, 793
 Lebre A-S, 117
 Lee CS, 298
 Lee V M-Y, 165
 Lees A, 665
 LeGuern E, 786
 Leigh PN, 643
 Leigh RJ, 24
 Lennon VA, 146
 Lenz O, 367
 Leschziner G, 433
 Levine SR, 688
 Levine SR, 736
 Lévy C, 411
 Lhatoo SD, 336

Li M, 532
 Li W, 776
 Lin L, 136
 Lipe H, 486
 Lipkin WI, 249
 Lochmuller H, 693
 Lodi R, 590
 Loeffen J, 195
 Loes DJ, 186
 Lombès A, 607
 Long DM, 817
 Lotharius J, 79
 Louis ED, 761
 Love S, 753
 Lozano AM, 155
 Lu J-Q, 298
 Lu M, 736
 Lublin FD, 677
 Lucas M, 529
 Lucchinetti C, 793
 Luciano D, 328
 Lüke W, 636
 Lyden PD, 736
 Lynch DR, 67
 Lyons K, 155

 Maass M, 585
 MacDonald BK, 336
 MacDonald ME, 29
 Maeda Y, 776
 Maertzdorf J, 104
 Magerl W, 493
 Magistris M, 214
 Maier W, 819
 Mandel H, 195
 Mander A, 665
 Manner TE, 110
 Manners D, 590
 Margolis RL, 117
 Marler JR, 736
 Martin E, 518
 Martin J-J, 245
 Maruyama M, 544
 Maruyama T, 242
 Marx J, 493
 Mascia A, 668
 Masliah E, 165
 Mastaglia FL, 320
 Masterman DM, 355
 Masters CL, 125
 Mathias CJ, 521
 Matsuda C, 130
 Matsui T, 544
 Matsumoto S, 138
 Matsuno S, 546
 Matsushita M, 486
 Matsushita S, 276
 Matsushita S, 544
 Mayeux R, 808
 Mayeux-Portas V, 267
 Mayne M, 727
 McArthur JC, 745
 McInnis M, 114
 McLean CA, 125
 Mega MS, 355
 Melberg A, 136

 Menonna J, 776
 Mentis M, 155
 Mersivanova I, 245
 Mesulam M-M, 425
 Metsähonkala EL, 110
 Metz LM, 650
 Mezaki T, 138
 Michel D, 214
 Mignot E, 136
 Miller JQ, 278
 Minassian BA, 271
 Minoshima S, 416
 Mizutani K, 138
 Moeller H-J, 545
 Mohr A, 460
 Moll GH, 393
 Mondell BE, 418
 Montalban X, 408
 Montori M, 529
 Moreno JD, 558
 Morgan DJ, 396
 Morikawa Y-I, 544
 Morita H, 546
 Morris C, 665
 Moser AB, 396
 Moser AB, 512
 Moser HW, 186
 Moser HW, 396
 Moser HW, 512
 Moshe SL, 328
 Moshe SL, 659
 Moslemi A-R, 377
 Mosnier J-F, 214
 Mufson EJ, 202
 Mukoyama I, 138
 Müller-Myhsok B, 121
 Mullin K, 114
 Murphy K, 682
 Muzik O, 618
 Myers RH, 29

 Na DK, 817
 Nagarajan L, 320
 Någren K, 110
 Naini A, 176
 Nakagawa M, 544
 Nakazato F, 242
 Nappi G, 525
 Narita Y, 501
 Naumann M, 121
 Naumann M, 405
 Nayak S, 24
 Nelis E, 245
 Nelson KB, 597
 Nelson PK, 575
 Ni W, 230
 Nicholson GA, 125
 Nicholson GA, 313
 Niederwieser G, 135
 Nishino S, 136

 Odaka M, 712
 Ogier De Baulny H, 607
 Oh AK, 800
 Ohnishi A, 712
 Okamura N, 544

 Oldfors A, 377
 Oliva R, 263
 Olivier A, 770
 O'Malley KL, 79
 Oppenheimer S, 555
 Orakcioglu B, 460
 Osame M, 544
 Osawa Y, 685
 Osterhaus ADME, 104
 Ottman R, 761
 Ozelius LJ, 367

 Palmer J, 130
 Pancioli A, 736
 Papassotiropoulos A, 819
 Parkkola RK, 110
 Parvizi J, 53
 Pastor E, 263
 Pastor P, 263
 Peeling J, 727
 Peo'ch K, 257
 Perini MP, 137
 Perrine K, 575
 Petersen RC, 421
 Petiot P, 214
 Petri Henske E, 67
 Petry H, 636
 Pfeiffer RF, 820
 Phillips TM, 597
 Picard F, 786
 Pickhardt M, 636
 Pike GB, 770
 Pohl D, 585
 Pohlers O, 460
 Portlance Walker M, 249
 Posner JB, 141
 Powell JF, 643
 Power C, 230
 Power C, 650
 Power C, 727
 Powers JM, 396
 Praamstra P, 797
 Pramstaller PP, 367
 Prud'Homme J-F, 786
 Pruszak-Seel R, 121
 Przedborski S, 176
 Ptok U, 819

 Quick KL, 627
 Quinn N, 665
 Quinn TC, 556
 Quistorff B, 672

 Rahman S, 805
 Rajagopalan B, 590
 Ramat S, 24
 Rao ML, 819
 Rapoport SI, 545
 Raskind W, 486
 Ratan RR, 345
 Rauhut U, 575
 Rausch W-D, 405
 Raymond GV, 186
 Raymond GV, 512
 Rebeck GW, 114
 Rebeck GW, 697

 Reilly M, 521
 Reiners K, 405
 Reingold SC, 677
 Resor SR, 328
 Reverter JC, 408
 Richter F, 7
 Rieckmann P, 405
 Rigamonti D, 682
 Ringleb PA, 460
 Ripley B, 136
 Rojas-García R, 130
 Romero N, 607
 Rosen R, 35
 Rosenbaum D, 328
 Rosenblatt DS, 396
 Rosoklja G, 176
 Ross CA, 117
 Ross CA, 14
 Rossini PM, 136
 Rossor AM, 433
 Rossor MN, 433
 Rothenberger A, 393
 Rothman SM, 721
 Rouleau GA, 267
 Rovari M, 415
 Ruth TJ, 298
 Ryssel H, 460
 Ryu H, 345

 Sakamoto T, 138
 Sakurai S, 546
 Salomons GS, 401
 Sander JWAS, 336
 Sándor PS, 668
 Sartor K, 460
 Sasaki H, 544
 Sasaki R, 501
 Sastre-Garriga J, 408
 Saxena R, 117
 Scahill RI, 433
 Scarlato G, 137
 Schable H-G, 7
 Schapira AHV, 590
 Schaumberg H, 817
 Scheithauer B, 67
 Schellenberg GD, 144
 Schellinger PD, 460
 Scherer SW, 271
 Schiess R, 384
 Schlaberg R, 249
 Schmidt RE, 396
 Schmitz S, 819
 Schneider J, 518
 Schoenen J, 668
 Schofield PR, 125
 Schulzer M, 298
 Schwab S, 460
 Schwaiger M, 813
 Seerp Baarsma G, 104
 Seidel L, 668
 Sengers R, 195
 Serrano-Munera C, 130
 Shahar EL, 278
 Shalev R, 278
 Shalinsky DR, 230
 Sharpe DM, 313

Shaw CE, 643
 Sheikh KA, 694
 Shibasaki H, 138
 Shill H, 540
 Shimada H, 546
 Shimohata T, 14
 Shinnar R, 659
 Shinnar S, 328
 Shinnar S, 659
 Shorvon SD, 336
 Shuck T, 165
 Silén T, 90
 Silva C, 230
 Silva C, 650
 Sinke RJ, 797
 Sipski ML, 35
 Smeets R, 195
 Smeitink J, 195
 Smith C, 808
 Smith KD, 512
 Smith KJ, 470
 Smith MJ, 125
 Snead OC, 288
 Solanky M, 776
 Solano F, 529
 Solbach W, 585
 Somers JT, 24
 Sormani MP, 415
 Sossi V, 298
 Spira PJ, 313
 Spitsin SV, 139
 Srinidhi J, 29
 Stadelmann C, 793
 Stebbins GT, 202
 Steen RG, 222
 Stefan K, 536
 Steiner T, 460
 Stephan C, 585
 Stevens JM, 433
 Stöckler-Ipsiroglu S, 195
 Stoessl AJ, 298
 Stoeter P, 493
 Strasser-Fuchs S, 135
 Strazzer S, 137
 Strotmann T, 367
 Styles P, 590
 Suehara M, 544
 Susuki K, 712

Sutton IJ, 253
 Tada T, 242
 Taga T, 685
 Tagawa Y, 712
 Takahashi H, 14
 Takahashi H, 712
 Takamatsu N, 138
 Takano T, 685
 Takeda A, 276
 Tamaoka A, 546
 Tamargo RJ, 682
 Tan C-T, 810
 Tanaka K, 686
 Tanaka M, 686
 Tang M-X, 808
 Tanzi R, 114
 Tarnopolsky MA, 561
 Taylor A, 98
 Taylor DJ, 590
 Taylor SAM, 29
 Teipel SJ, 545
 Teismann P, 176
 Tekin S, 355
 Tennekoon G, 688
 Terry RD, 684
 Terwindt GM, 753
 Thayaparan T, 810
 Thickbroom GW, 320
 Thiel T, 518
 Thomas PK, 521
 Thömke F, 493
 Thompson KA, 745
 Thompson S, 222
 Tilley BC, 736
 Timmerman V, 245
 Tintoré M, 408
 Tiranti V, 106
 Tojo M, 544
 Tokuda T, 546
 Tolosa E, 263
 Tomasini L, 328
 Tong X, 260
 Torn-Broers Y, 45
 Touboul P-J, 411
 Treede R-D, 493
 Treib J, 585
 Trijbels F, 195

Trojanowski JQ, 165
 Trott G-E, 393
 Tsuji S, 14
 Tulinius M, 377
 Tzourio C, 411
 Ueda S, 712
 Urban P, 493
 Valente EM, 362
 Valentino LA, 98
 Van Alfen N, 797
 Van Broeckhoven C, 245
 Van Deerlin VMD, 165
 Van Den Heuvel L, 195
 Van Den Maagdenberg AMJM, 753
 Van Der Lelij A, 104
 Van Eimeren T, 813
 Van Geel BM, 186
 Van Hoesen GW, 53
 Vanhatalo S, 277
 Vaughan J, 665
 Vela R, 263
 Verbeek MM, 685
 Verhoeven NM, 401
 Verjans GMGM, 104
 Verma IC, 117
 Vermeulen FMLG, 753
 Verrips A, 685
 Vieregge P, 367
 Vincent A, 253
 Vinters HV, 355
 Vinters HV, 691
 Vissing J, 672
 Vogelsberg-Ragaglia V, 165
 Voit T, 685
 Vonsattel J-P, 29
 Vonsattel JPG, 697

Wagner KR, 706
 Walker MC, 260
 Wallace S, 328
 Walls TJ, 443
 Wang WC, 222
 Warren KG, 650
 Watkins PR, 512
 Weber F, 636

Weber T, 636
 Wee Yong V, 230
 Weigell-Weber M, 384
 Weiler LJ, 29
 Weishaupt A, 405
 Welaratne A, 257
 Wesselingh SL, 745
 Whelan C, 808
 White R, 67
 Whitwell JL, 433
 Wiendl H, 281
 Willemse MAAP, 685
 Wilson CJ, 805
 Wirth S, 393
 Wolff J, 486
 Wolinsky JS, 290
 Wolinsky JS, 415
 Wong B, 401
 Wood JD, 14
 Wood N, 665
 Wood NW, 362
 Wood NW, 521

X-Tang M, 761

Yabana T, 501
 Yamada M, 14
 Yamada M, 712
 Yamada Y, 242
 Yan H-J, 727
 Yang X-F, 721
 Yhu S, 114
 Yohai D, 328
 Young EJ, 271
 Young P, 636
 Yu Z, 146
 Yuen E, 486
 Yuki N, 712

Zaman K, 345
 Zander C, 117
 Zayas MD, 529
 Zeviani M, 106
 Zhang K, 230
 Zhukareva V, 165
 Zimprich A, 121
 Zinkowski R, 545
 Zwarts, MJ 797

Subject Index

N-Acetylaspartate

absence of *N*-acetylaspartate in the human brain: impact on neurospectroscopy? (Martin et al) 2001;49:518
N-acetyl aspartate—a neuronal marker? (Barker) 2001;49:423 (Editorial)

Acetylcholinesterase

central acetylcholinesterase inhibition in Alzheimer patients (Imbimbo) 2001;49:416 (Letter)

ACTH

corticotropin (ACTH) acts directly on amygdala neurons to down-regulate corticotropin-releasing hormone gene expression (Brunson et al) 2001;49:304
how does ACTH work against infantile spasms? Bedside to bench (Snead) 2001;49:288 (Editorial)

Adenosine

adenosine A₁ and A_{2A} receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage (Mayne et al) 2001;49:EEE
diminished adenosine A₁ receptor expression on macrophages in brain and blood of patients with multiple sclerosis (Johnston et al) 2001;49:650

Adrenocorticotrophic hormone; see ACTH

Adrenoleukodystrophy

adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening (Bezman et al) 2001;49:512
evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy (Van Geel et al) 2001;49:186

Aging; see also Elderly

potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

AIDS; see HIV-1

Alpers' syndrome

sequence-selective DNA binding drugs mithramycin A and chromomycin A₂ are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons (Chatterjee et al) 2001;49:345

Alzheimer's disease

cathepsin D polymorphism not associated with Alzheimer's disease in Japan (Matsui et al) 2001;49:544 (Letter)
focal dementia syndromes: in search of the gold standard (Petersen) 2001;49:421 (Editorial)
honorable compromise regarding amyloid in Alzheimer's disease (Terry) 2001;49:684 (Letter)
lack of association of the interleukin-1 β gene polymorphism with Alzheimer's disease in a Korean population (Ki et al) 2001;49:UUU (Letter)
orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease (Tekin et al) 2001;49:355
patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease (Chan et al) 2001;49:433

role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease (Heneka et al) 2001;49:276 (Letter)

tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231 (Hampel et al) 2001;49:545 (Letter)

Alzheimer's disease, genetics

no evidence for genetic association or linkage of the cathepsin D (CTSD) exon 2 polymorphism and Alzheimer disease (Bertram et al) 2001;49:114
selective vulnerability of brainstem nuclei to Alzheimer's disease (Parvizi et al) 2001;49:53

Alzheimer's disease, pathology

central acetylcholinesterase inhibition in Alzheimer patients (Imbimbo) 2001;49:416 (Letter)
selective vulnerability of brainstem nuclei to Alzheimer's disease (Parvizi et al) 2001;49:53
variable phenotype of Alzheimer's disease with spastic paraparesis (Smith et al) 2001;49:125

Amphetamine

role of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity (Lotharius and O'Malley) 2001;49:79

Amyloid

cerebral amyloid angiopathy: a microvascular link between parenchymal and vascular dementia? 2001;49:GGG (Editorial)

honorable compromise regarding amyloid in Alzheimer's disease (Terry) 2001;49:684 (Letter)

novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy (Grabowski et al) 2001;49:HHH

plasma levels of amyloid β proteins did not differ between subjects taking statins and those not taking statins (Tokuda et al) 2001;49:546 (Letter)

Amyotrophic lateral sclerosis

absence of echovirus sequences in brain and spinal cord of amyotrophic lateral sclerosis patients (Walker et al) 2001;49:249

compound heterozygous D90A and D96N SOD1 mutations in a recessive amyotrophic lateral sclerosis family (Hand et al) 2001;49:267

effects of riluzole on cortical excitability in patients with amyotrophic lateral sclerosis (Stefan et al) 2001;49:536
familial amyotrophic lateral sclerosis and parkinsonism-dementia complex of the Kii Peninsula of Japan: clinical and neuropathological study and tau analysis (Kuzuhara et al) 2001;49:501

increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis (Almer et al) 2001;49:176

intron 7 retention and exon 9 skipping EAAT2 mRNA variants are not associated with amyotrophic lateral sclerosis (Flowers et al) 2001;49:643

Aneurysm

treatment of intracranial aneurysm: surgical clipping or endovascular coiling? (Tamargo et al) 2001;49:682 (Letter)

Angelman syndrome

decreased binding of [^3H]*UC*flumazenil in Angelman syndrome patients with GABA_A receptor β 3 subunit deletions (Holopainen et al) 2001;49:110

Angioma

germline mutations in the *CCM1* gene, encoding Krit1, cause cerebral cavernous malformations (Lucas et al) 2001;49:529

Annals of Neurology

message from the editor (Johnson) 2001;49:1 (Editorial)

Antibodies

anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis (Sastre-Garriga et al) 2001;49:408

anti-Yo antibodies and cerebellar degeneration in a man with adenocarcinoma of the esophagus (Sutton et al) 2001;49:253

CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity (Yu et al) 2001; 49:146

paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy (Antoine et al) 2001;49:214

yet another paraneoplastic antibody (Posner and Dalmau) 2001;49:141 (Editorial)

Anticardiolipin antibodies

anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis (Sastre-Garriga et al) 2001;49:408

Antioxidants

antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia (Lodi et al) 2001;49:590

potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

Aphasia

primary progressive aphasia (Mesulam) 2001;49:425

Apolipoprotein E

apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke (Broderick et al) 2001;49:736

Parkinson's disease is not associated with the combined (alpha symbol)-synucleinapolipoprotein E susceptibility genotype (Khan et al) 2001;49:665

Apoptosis

adenosine A₁D₁A₂D₂D receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage (Mayne et al) 2001;49:EEE correlation between neurological progression and astrocyte apoptosis in HIV-associated dementia (Thompson et al) 2001;49:745

potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

sequence-selective DNA binding drugs mithramycin A and chromomycin A₃D are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons (Chatterjee et al) 2001;49: 345

Astrocytes

correlation between neurological progression and astrocyte apoptosis in HIV-associated dementia (Thompson et al) 2001;49:745

Ataxia

antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia (Lodi et al) 2001;49:590

intermediate CAG repeat lengths (53,54) for MJD/SCA3 are associated with an abnormal phenotype (Alfen et al) 2001;49:797

slowing of voluntary and involuntary saccades: an early sign in spinocerebellar ataxia type 7 (Oh et al) 2001; 49:800

Ataxia telangiectasia

superoxide stress identifies neurons at risk in a model of ataxia-telangiectasia (Quick and Dugan) 2001;49:627

Atrophin-1

widespread occurrence of intranuclear atrophin-1 accumulations in the CNS neurons of patients with dentatorubral-pallidolysian atrophy (Yamada et al) 2001;49:14

Atrophy

loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment (Korlower et al) 2001;49:202

patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease (Chan et al) 2001;49:433

widespread occurrence of intranuclear atrophin-1 accumulations in the CNS neurons of patients with dentatorubral-pallidolysian atrophy (Yamada et al) 2001;49:14

Attention deficit-hyperactivity disorder

children with comorbid attention-deficit-hyperactivity disorder and tic disorder: evidence for additive inhibitory deficits within the motor system (Moll et al) 2001;49: 393

Aura

migraine, aura, and cortical spreading depression: why are we still talking about it? (Goadsby) 2001;49:4 (Editorial)

Autism

neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation (Nelson et al) 2001;49:597

Autoantibodies

CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity (Yu et al) 2001; 49:146

Autonomic nervous system

hemispheric influence on autonomic modulation and baroreflex sensitivity (Hilz et al) 2001;49:575

Autonomic neuropathy

a novel TRK A (*NTRK1*) mutation associated with hereditary sensory and autonomic neuropathy type V (Houlden) 2001;49:521

Axons

electrically active axons degenerate when exposed to nitric oxide (Smith et al) 2001;49:470

Baroreflexes

hemispheric influence on autonomic modulation and baroreflex sensitivity (Hilz et al) 2001;49:575

Basal ganglia

subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease (Blandini et al) 2001;49:525

Books

Aids to the Examination of the Peripheral Nervous System, 4th ed by O'Brien (Johnson) 2001;49:820

Alzheimer Disease: The Changing View by Katzman and Bick (Breitner) 2001;49:418

Alzheimer's Disease: The Changing View by Katzman and Bick 2001;49:418
Atlas of Digital Polysomnography by Geyer et al (Allen) 2001;49:548
Brain Mapping: The Disorders edited by Mazziotta et al (Hillis) 2001;49:551
Brain Mapping: The Systems edited by Toga and Mazziotta (Hillis) 2001;49:551
Central Nervous System Angitis by Schmidley (Levine) 2001;49:688
Cluster Headache and Related Conditions, edited by Olesen and Goadsby (Mondell) 2001;49:418
Cluster Headache and Related Conditions edited by Olesen and Goadsby (Mondell) 2001;49:418
Comprehensive Clinical Neurophysiology by Luders and Levin (Conwit) 2001;49:549
Developmental Disability & Behavior edited by Gillberg and O'Brien (Kinsman) 2001;49:549
GABA in the Nervous System: The View at 50 Years edited by Olsen (Kapur) 2001;49:820
Infectious Diseases of the Nervous System edited by Davis and Kennedy (Johnson) 2001;49:552
Molecular Mechanisms of Neurodegenerative Diseases edited by Chesselet (Koo) 2001;49:551
Neurobiology of Spinal Cord Injury by Kalb and Strittmatter (Tennekoon) 2001;49:688
Neuroimaging edited by Orrison (Masdeu) 2001;49:550
Neurology of Eye Movements, 3rd ed by Leigh and Zee (Sharpe) 2001;49:548
Neurology of the Newborn, 4th ed. by Volpe (Ferriero) 2001;49:820
New Concepts in the Immunopathogenesis of CNS Infections edited by Peterson and Remington (Johnson) 2001;49:552
Parkinson's Disease and Movement Disorders edited by Adler & Ahlskog (Pfeiffer) 2001;49:821
The Practice of Neural Science from Synapses to Symptoms by Brust (Miller) 2001;49:279
Principles of Behavioral and Cognitive Neurology, 2nd ed, edited by Mesulam (Cummings) 2001;49:280
Reading and Attention Disorders edited by Duane (Cutting) 2001;49:279

Brainstem

selective vulnerability of brainstem nuclei to Alzheimer's disease (Parvizi et al) 2001;49:53

Cancer

anti-Yo antibodies and cerebellar degeneration in a man with adenocarcinoma of the esophagus (Sutton et al) 2001;49:253

CRMP-5 neuronal autoantibody: marker for lung cancer and thymoma-related autoimmunity (Yu et al) 2001;49:146

paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy (Antoine et al) 2001;49:214

yet another paraneoplastic antibody (Posner and Dalmau) 2001;49:141 (Editorial)

Cardiomyopathy

antioxidant treatment improves *in vivo* cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia (Lodi et al) 2001;49:590

mutations in the complex I *NDUFS2* gene of patients with cardiomyopathy and encephalomyopathy (Loeffen et al) 2001;49:195

Cardiovascular system

forebrain lateralization of cardiovascular function: physiology and clinical correlates (Oppenheimer) 2001;49:555 (Editorial)

hemispheric influence on autonomic modulation and baroreflex sensitivity (Hilz et al) 2001;49:575

Carnitine

potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

Cathepsin D

cathepsin D polymorphism not associated with Alzheimer's disease in Japan (Matsui et al) 2001;49:544 (Letter)

no evidence for genetic association or linkage of the cathepsin D (*CTSD*) exon 2 polymorphism and Alzheimer disease (Bertram et al) 2001;49:114

Cerebellar ataxia

glutelin sensitivity in sporadic and hereditary cerebellar ataxia (Bushara et al) 2001;49:540

Cerebellar disease

anti-Yo antibodies and cerebellar degeneration in a man with adenocarcinoma of the esophagus (Sutton et al) 2001;49:253

are transfected cells essential for measuring cytotoxic T cells in paraneoplastic cerebellar degeneration? (Tanaka and Tanaka) 2001;49:686 (Letter)

SCA12 is a rare locus for autosomal dominant cerebellar ataxia: a study of an Indian family (Fujigasaki et al) 2001;49:117

subclinical cerebellar impairment in the common types of migraine: a three-dimensional analysis of reaching movements (Sándor et al) 2001;49:668

Cerebral amyloid angiopathy

cerebral amyloid angiopathy: a microvascular link between parenchymal and vascular dementia? (Vinters) 2001;49:691 (Editorial)

novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy (Grabowski et al) 2001;49:697

Cerebral blood flow

low cerebral blood flow velocity and risk of white matter hyperintensities (Tzourio et al) 2001;49:411

Cerebral cavernous angioma

germline mutations in the *CCM1* gene, encoding Krit1, cause cerebral cavernous malformations (Lucas et al) 2001;49:529

Cerebral cortex

differences in sensory and motor cortical organization following brain injury early in life (Thickbroom et al) 2001;49:320

migraine, aura, and cortical spreading depression: why are we still talking about it? (Goadsby) 2001;49:4 (Editorial)

right lateralized motor cortex activation during volitional blinking (Eimeren et al) 2001;49:813

selective alterations in glutamate and GAGA receptor subunit mRNA expression in dysplastic neurons and giant cells of cortical tubers (White et al) 2001;49:67

sequence-selective DNA binding drugs mithramycin A and chromomycin A₂D are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons (Chatterjee et al) 2001;49:345

Cerebral edema

delayed cerebral edema and fatal coma after minor head trauma: role of CACNA1A calcium channel subunit

gene and relationship with familial hemiplegic migraine (Kors et al) 2001;49:753

Cerebral hemorrhage

adenosine A₁ and D₂ receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage (Mayne et al) 2001;49:727

Cerebral infarction

mechanisms and predictors of chronic facial pain in lateral medullary infarction (Fitzek et al) 2001;49:493

Cerebral ischemia

improved cerebrovascular patency following therapy in patients with sickle cell disease: initial results in 4 patients who received HLA-identical hematopoietic stem cell allografts (Steen et al) 2001;49:222

stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia (Schellinger et al) 2001;49:460

Cerebral lateralization

hemispheric influence on autonomic modulation and baroreflex sensitivity (Hilz et al) 2001;49:575

Cerebral palsy

differences in sensory and motor cortical organization following brain injury early in life (Thickbroom et al) 2001;49:320

Cerebrospinal fluid

14-3-3 protein cerebrospinal fluid detection in human growth hormone-treated Creutzfeldt-Jakob disease (Brandel et al) 2001;49:257

cerebrospinal fluid interleukin-6 levels in hypertensive encephalopathy: a possible marker of disease activity (Takanoy et al) 2001;49:685 (Letter)

hyponatremia: a simple clue, simply missed (Willemsen et al) 2001;49:685 (Letter)

presence of *Chlamydia pneumoniae* DNA in the cerebrospinal fluid is a common phenomenon in a variety of neurological diseases and not restricted to multiple sclerosis (Gieffers et al) 2001;49:585

tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231 (Hampel et al) 2001;49:545 (Letter)

Cerebrovascular disorders

apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke (Broderick et al) 2001;49:736

improved cerebrovascular patency following therapy in patients with sickle cell disease: initial results in 4 patients who received HLA-identical hematopoietic stem cell allografts (Steen et al) 2001;49:222

stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia (Schellinger et al) 2001;49:460

tracking post-stroke recovery with magnetoencephalography (Rossini) 2001;49:136 (Letter)

Ceruloplasmin

decreased serum ceruloplasmin and copper levels in cervical dystonia (Mezaki et al) 2001;49:138 (Letter)

Cervical dystonia

decreased serum ceruloplasmin and copper levels in cervical dystonia (Mezaki et al) 2001;49:138 (Letter)

Charcot-Marie-Tooth disease

further evidence that neurofilament light chain gene mutations can cause Charcot-Marie-Tooth disease type 2E (De Jonghe et al) 2001;49:245

Children

care should be taken in interpretation of visual field tests in children (Vanhalto) 2001;49:277 (Letter)

children with comorbid attention-deficit-hyperactivity disorder and tic disorder: evidence for additive inhibitory deficits within the motor system (Moll et al) 2001;49:393

how long do new-onset seizures in children last? (Shinnar et al) 2001;49:659

neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation (Nelson et al) 2001;49:597

postnatal maturation of human GAGA₁D₂D receptors measured with positron emission tomography (Chugani et al) 2001;49:618

Chlamydia pneumoniae

Chlamydia pneumoniae and multiple sclerosis: innocent bystander or culprit? (Quinn) 2001;49:557 (Editorial)

Chlamydia pneumoniae-specific humoral immune responses and clinical disease parameters in multiple sclerosis (Krammer et al) 2001;49:135 (Letter)

presence of *Chlamydia pneumoniae* DNA in the cerebral spinal fluid is a common phenomenon in a variety of neurological diseases and not restricted to multiple sclerosis (Gieffers et al) 2001;49:585

Chromomycin A3

sequence-selective DNA binding drugs mithramycin A and chromomycin A₃D are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons (Chatterjee et al) 2001;49:345

Clinical trials

placebo-controlled clinical trials in multiple sclerosis: ethical considerations (Lublin et al) 2001;49:677

placebos on trial (Moreno) 2001;49:558 (Editorial)

Cobalamin

neurological and neuropathological heterogeneity in two brothers with cobalamin C deficiency (Powers et al) 2001;49:396

Coenzyme Q10

antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia (Lodi et al) 2001;49:590

potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

Coma

delayed cerebral edema and fatal coma after minor head trauma: role of CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine (Kors et al) 2001;49:753

Convulsions; see Seizures

Copper

decreased serum ceruloplasmin and copper levels in cervical dystonia (Mezaki et al) 2001;49:138 (Letter)

reduction of Menkes mRNA and copper in leukocytes of patients with primary adult-onset dystonia (Kruse et al) 2001;49:405

Cortical dysplasia

texture analysis of morphological processing of magnetic resonance imaging assist detection of focal cortical dysplasia in extra-temporal partial epilepsy (Bernaconi et al) 2001;49:770

Cortical spreading depression

is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache? (Ebersberger et al) 2001;49:7 migraine, aura, and cortical spreading depression: why are we still talking about it? (Goadsby) 2001;49:4

Corticotropin; see ACTH**Creatine**

irreversible brain creatine deficiency with elevated serum and urine creatine: a creatine transporter defect? (Cecil et al) 2001;49:401

potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

Creutzfeldt-Jakob disease

14-3-3 protein cerebrospinal fluid detection in human growth hormone-treated Creutzfeldt-Jakob disease (Brandel et al) 2001;49:257

Cyclooxygenase-2

increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis (Almer et al) 2001;49:176

Deep brain stimulation

deep brain stimulation for Parkinson's disease (Delong and Wichmann) 2001;49:142 (Editorial)

functional correlates of pallidal stimulation for Parkinson's disease (Fukuda et al) 2001;49:155

Dementia

the case of the missing tau, or, why didn't the mRNA bark? (Bird and Schellenberg) 2001;49:144 (Editorial)

cerebral amyloid angiopathy: a microvascular link between parenchymal and vascular dementia? (Vinters) 2001;49:691 (Editorial)

correlation between neurological progression and astrocyte apoptosis in HIV-associated dementia (Thompson et al) 2001;49:745

familial amyotrophic lateral sclerosis and parkinsonism-dementia complex of the Kii Peninsula of Japan: clinical and neuropathological study and tau analysis (Kuzuhara et al) 2001;49:501

familial atypical progressive supranuclear palsy associated with homozygosity for the delN296 mutation in the tau gene (Pastor et al) 2001;49:263

focal dementia syndromes: in search of the gold standard (Petersen) 2001;49:421 (Editorial)

HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors (Johnston et al) 2001;49:230

loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment (Kordower et al) 2001;49:202

loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia (Zhukareva et al) 2001;49:165

novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy (Grabowski et al) 2001;49:697

patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease (Chan et al) 2001;49:433

Dentatorubral-pallidoluysian atrophy

widespread occurrence of intranuclear atrophin-1 accumulations in the CNS neurons of patients with dentatorubral-pallidoluysian atrophy (Yamada et al) 2001;49:14

Depression

is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache? (Ebersberger et al) 2001;49:7

migraine, aura, and cortical spreading depression: why are we still talking about it? (Goadsby) 2001;49:4 (Editorial)

Desmin

abnormal desmin protein in myofibrillar myopathies caused by desmin gene mutations (Li and Dalakas) 2001;49:532

Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) 122-123,123t

Dichloroacetate

potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

DNA

sequence-selective DNA binding drugs mithramycin A and chromomycin A/d3D are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons (Chatterjee et al) 2001;49:345

DNA, mitochondrial

Down's syndrome fibroblasts anticipate the accumulation of specific ageing-related mtDNA mutations (Del Bo et al) 2001;137:138

incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA abnormalities (Darin et al) 2001;49:377

late-onset mitochondrial DNA depletion: DNA copy number, multiple deletions, and compensation (Barthélémy et al) 2001;49:607

novel mtDNA mutation in the ND5 subunit of complex I in two MELAS patients (Corona et al) 2001;49:106

Dopamine

biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover (Fuente-Fernández et al) 2001;49:298

no evidence of association between a dopamine transporter gene polymorphism (1215A/G) and Parkinson's disease (Kimura et al) 2001;49:276 (Letter)

positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the *Parkin* gene (Hilker et al) 2001;49:367

role of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity (Lotharius and O'Malley) 2001;49:79

Down regulation

corticotropin (ACTH) acts directly on amygdala neurons to down-regulate corticotropin-releasing hormone gene expression (Brunson et al) 2001;49:304

Down's syndrome

Down's syndrome fibroblasts anticipate the accumulation of specific ageing-related mtDNA mutations (Del Bo et al) 2001;137:138

Drug therapy

placebos on trial (Moreno) 2001;49:558 (Editorial)

Dyskinesia

facial dyskinesia and facial myokymia (FDFM): a novel movement disorder (Fernandez et al) 2001;49:486

Dystonia

abnormal activity in the globus pallidus in off-period dystonia (Hashimoto et al) 2001;49:242

decreased serum ceruloplasmin and copper levels in cervical dystonia (Mezaki et al) 2001;49:138 (Letter)

DYT13, a novel primary torsion dystonia locus, maps to chromosome 1p36.13-36.32 in an Italian family with cranial-cervical or upper limb onset (Valente et al) 2001;49:362

reduction of Menkes mRNA and copper in leukocytes of patients with primary adult-onset dystonia (Kruse et al) 2001;49:405

Echoviruses

absence of echovirus sequences in brain and spinal cord of amyotrophic lateral sclerosis patients (Walker et al) 2001;49:249

Elderly

loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment (Kornder et al) 2001;49:202

Encephalitis

HSV-1-induced retinitis following herpes simplex encephalitis: indications for brain-to-eye transmission of HSV-1 (Maertzdorf et al) 2001;49:104

treatment of acute Nipah encephalitis with ribavirin (Chong et al) 2001;49:810

Encephalomyopathy

incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA abnormalities (Darin et al) 2001;49:377

Encephalopathy

cerebrospinal fluid interleukin-6 levels in hypertensive encephalopathy: a possible marker of disease activity (Takanaka et al) 2001;49:685 (Letter)

mutations in the complex I *NDUFS2* gene of patients with cardiomyopathy and encephalomyopathy (Loeffen et al) 2001;49:195

Epilepsy

bruising and the ketogenic diet: evidence for diet-induced changes in platelet function (Berry-Kravis et al) 2001;49:98

causes of epilepsies: insights from discordant monozygotic twins (Briellmann et al) 2001;49:45

evidence for digenic inheritance in a family with both febrile convulsions and temporal lobe epilepsy implicating chromosomes 18qter and 1q25-q31 (Baulac et al) 2001;49:786

genome scan of idiopathic generalized epilepsy: evidence for major susceptibility gene and modifying genes influencing the seizure type (Durner et al) 2001;49:328

lack of activation of human secondary somatosensory cortex in Unverricht-Lundborg type of progressive myoclonus epilepsy (Forss et al) 2001;49:90

laforin is a cell membrane and endoplasmic reticulum-associated protein tyrosine phosphatase (Minassian et al) 2001;49:271

mortality in epilepsy in the first 11 to 14 years after diagnosis: multivariate analysis of a long-term, prospective, population-based cohort (Lhatoo et al) 2001;49:336

propofol in subanesthetic doses terminates status epilepticus in a rodent model (Holtkamp et al) 2001;49:260

selective alterations in glutamate and GABA receptor subunit mRNA expression in dysplastic neurons and giant cells of cortical tubers (White et al) 2001;49:67

texture analysis of morphological processing of magnetic resonance imaging assist detection of focal cortical dysplasia in extra-temporal partial epilepsy (Bernaconi et al) 2001;49:770

Erratum

factors predicting prognosis of epilepsy after presentation with seizures (MacDonald et al) 2001;49:547

Essential tremor

risk of tremor and impairment from tremor in relatives of patients with essential tremor: a community-based family study (Louis et al) 2001;49:761

Eye movements

ocular oscillations induced by shifts of the direction and depth of visual fixation (Bhidayasi et al) 2001;49:24

Familial dyskinesia and facial myokymia

familial dyskinesia and facial myokymia (FDFM): a novel movement disorder (Fernandez et al) 2001;49:486

Flumazenil

decreased binding of [³H]flumazenil in Angelman syndrome patients with GABA_A receptor $\beta\delta\gamma$ subunit deletions (Holopainen et al) 2001;49:110

Focal cortical dysplasia

texture analysis of morphological processing of magnetic resonance imaging assist detection of focal cortical dysplasia in extra-temporal partial epilepsy (Bernaconi et al) 2001;49:770

Forebrain

forebrain lateralization of cardiovascular function: physiology and clinical correlates (Oppenheimer) 2001;49:555 (Editorial)

Friedreich's ataxia

antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia (Lodi et al) 2001;49:590

Frontotemporal dementia

the case of the missing tau, or, why didn't the mRNA bark? (Bird and Schellenberg) 2001;49:144 (Editorial)

loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia (Zhukareva et al) 2001;49:165

GABA

postnatal maturation of human GABA_A receptors measured with positron emission tomography (Chugani et al) 2001;49:618

GABA receptor

decreased binding of [³H]flumazenil in Angelman syndrome patients with GABA_A receptor $\beta\delta\gamma$ subunit deletions (Holopainen et al) 2001;49:110

selective alterations in glutamate and GABA receptor subunit mRNA expression in dysplastic neurons and giant cells of cortical tubers (White et al) 2001;49:67

Gangliosides

animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside (Yuki et al) 2001;49:712

Genetic mutations: *see* Mutations

Gentamicin

gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations (Wagner et al) 2001;49:706

when running a stop sign may be a good thing (Karpati) 2001;49:693 (Editorial)

Ginkgo biloba

potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

Glatiramer acetate

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on MRI-measured disease activity and

burden in patients with relapsing multiple sclerosis (Comi et al) 2001;49:290

Global Assessment of Functioning (GAF) Scale_123,124t

Globus pallidus
abnormal activity in the globus pallidus in off-period dystonia (Hashimoto et al) 2001;49:242

Glucose
hypoglycorrachia: a simple clue, simply missed (Willemse et al) 2001;49:685 (Letter)

Glutamate
intron 7 retention and exon 9 skipping EAAT2 mRNA variants are not associated with amyotrophic lateral sclerosis (Flowers et al) 2001;49:643
selective alterations in glutamate and GAGA receptor subunit mRNA expression in dysplastic neurons and giant cells of cortical tubers (White et al) 2001;49:67

GM1 ganglioside
animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside (Yuki et al) 2001;49:712

Guillain-Barré syndrome
animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside (Yuki et al) 2001;49:712

Headache
delayed cerebral edema and fatal coma after minor head trauma: role of CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine (Kors et al) 2001;49:753
is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache? (Ebersberger et al) 2001;49:7
migraine, aura, and cortical spreading depression: why are we still talking about it? (Goadsby) 2001;49:4
subclinical cerebellar impairment in the common types of migraine: a three-dimensional analysis of reaching movements (Sándor et al) 2001;49:668

Head trauma
delayed cerebral edema and fatal coma after minor head trauma: role of CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine (Kors et al) 2001;49:753

Heart
antioxidant treatment improves *in vivo* cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia (Lodi et al) 2001;49:590

Hemispheric lateralization
hemispheric influence on autonomic modulation and baroreflex sensitivity (Hilz et al) 2001;49:575
right lateralized motor cortex activation during volitional blinking (Eimeren et al) 2001;49:813

Herpes simplex virus
HSV-1-induced retinitis following herpes simplex encephalitis: indications for brain-to-eye transmission of HSV-1 (Maertzdorf et al) 2001;49:104

Human immunodeficiency virus
correlation between neurological progression and astrocyte apoptosis in HIV-associated dementia (Thompson et al) 2001;49:745
HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors (Johnston et al) 2001;49:230

Huntington's disease
quantitative neuropathological changes in presymptomatic Huntington's disease (Gómez-Tortosa et al) 2001;49:29

Hypertensive encephalopathy
cerebrospinal fluid interleukin-6 levels in hypertensive encephalopathy: a possible marker of disease activity (Takanaka et al) 2001;49:685 (Letter)

Hypocretin
hypocretin deficiency in familial symptomatic narcolepsy (Melberg et al) 2001;49:136 (Letter)

Hypoglycorrachia
hypoglycorrachia: a simple clue, simply missed (Willemse et al) 2001;49:685 (Letter)

Interleukin-1
gene polymorphisms of interleukin-1(alpha symbol) influence the course of Alzheimer's disease (Kölsch et al) 2001;49:818 (Letter)
lack of association of the interleukin-1(alpha symbol) gene polymorphism with Alzheimer's disease in a Korean population (Ki et al) 2001;49:817 (Letter)

Interleukin-6
cerebrospinal fluid interleukin-6 levels in hypertensive encephalopathy: a possible marker of disease activity (Takanaka et al) 2001;49:685 (Letter)

Japan
cathepsin D polymorphism not associated with Alzheimer's disease in Japan (Matsui et al) 2001;49:544 (Letter)
familial amyotrophic lateral sclerosis and parkinsonism-dementia complex of the Kii Peninsula of Japan: clinical and neuropathological study and tau analysis (Kuzuhara et al) 2001;49:501

Kearns Sayre syndrome
late-onset mitochondrial DNA depletion: DNA copy number, multiple deletions, and compensation (Barthélémy et al) 2001;49:607

Ketogenic diet
bruising and the ketogenic diet: evidence for diet-induced changes in platelet function (Berry-Kravis et al) 2001;49:98

Korea
lack of association of the interleukin-1(alpha symbol) gene polymorphism with Alzheimer's disease in a Korean population (Ki et al) 2001;49:817 (Letter)

Lactic acidosis
exercise intolerance in mitochondrial myopathy is not related to lactic acidosis (Vissing et al) 2001;49:672

Lafora disease
laforin is a cell membrane and endoplasmic reticulum-associated protein tyrosine phosphatase (Minassian et al) 2001;49:271

Leigh's syndrome
sequence-selective DNA binding drugs mithramycin A and chromomycin A λ d3D are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons (Chatterjee et al) 2001;49:345

Leukodystrophy
SURF1 gene mutation presenting as isolated leukodystrophy (Rahman et al) 2001;49:805

Levodopa
the neurochemistry of therapeutics: levodopa pharmacodynamics in Parkinson's disease (Frey) 2001;49:285 (Editorial)

Lipoic acid

potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

Lung cancer

CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity (Yu et al) 2001;49:146

Machado-Joseph disease

intermediate CAG repeat lengths (53,54) for MJD/SCA3 are associated with an abnormal phenotype (Alfen et al) 2001;49:797

Magnetic resonance imaging

absence of *N*-acetylaspartate in the human brain: impact on neurospectroscopy? (Martin et al) 2001;49:518

N-acetyl aspartate-a neuronal marker? (Barker) 2001;49:423 (Editorial)

effects of seasons on magnetic resonance imaging measured disease activity in patients with multiple sclerosis (Rovaris et al) 2001;49:415 (Letter)

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on MRI-measured disease activity and burden in patients with relapsing multiple sclerosis (Comi et al) 2001;49:290

a longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions (Bitsch et al) 2001;49:793

perfusion magnetic resonance abnormalities in patients with sickle cell disease (Kirkham et al) 2001;49:477

stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia (Schellinger et al) 2001;49:460

texture analysis of morphological processing of magnetic resonance imaging assist detection of focal cortical dysplasia in extra-temporal partial epilepsy (Bernaconi et al) 2001;49:770

Magnetic resonance spectroscopy

irreversible brain creatine deficiency with elevated serum and urine creatine: a creatine transporter defect? (Cecil et al) 2001;49:401

Magnetoencephalography

tracking post-stroke recovery with magnetoencephalography (Rossini) 2001;49:136 (Letter)

Matrix metalloproteinases

HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors (Johnston et al) 2001;49:230

McLeod syndrome

McLeod syndrome: a novel mutation, predominant psychiatric manifestations, and distinct striatal imaging findings (Jung et al) 2001;49:384

MELAS syndrome

novel mtDNA mutation in the ND5 subunit of complex I in two MELAS patients (Corona et al) 2001;49:106

Menkes protein

reduction of Menkes mRNA and copper in leukocytes of patients with primary adult-onset dystonia (Kruse et al) 2001;49:405

Mental retardation

neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation (Nelson et al) 2001;49:597

Mental status examination 122

format for 122f

Messenger RNA; see RNA, messenger

Migraine

delayed cerebral edema and fatal coma after minor head trauma: role of CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine (Kors et al) 2001;49:753

is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache? (Ebersberger et al) 2001;49:7 migraine, aura, and cortical spreading depression: why are we still talking about it? (Goadsby) 2001;49:4 Editorial subclinical cerebellar impairment in the common types of migraine: a three-dimensional analysis of reaching movements (Sádor et al) 2001;49:668

Mithramycin A

sequence-selective DNA binding drugs mithramycin A and chromomycin A₂D are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons (Chatterjee et al) 2001;49:345

Mitochondria

exercise intolerance in mitochondrial myopathy is not related to lactic acidosis (Vissing et al) 2001;49:672

incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA abnormalities (Darin et al) 2001;49:377 role of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity (Lotharius and O'Malley) 2001;49:79

Mitochondrial DNA see DNA, mitochondrial

MK801

subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease (Blandini et al) 2001;49:525

Motor cortex

right lateralized motor cortex activation during voluntary blinking (Eimeren et al) 2001;49:813

Motor hyperactivity

children with comorbid attention deficit-hyperactivity disorder and tic disorder: evidence for additive inhibitory deficits within the motor system (Moll et al) 2001;49:393

Movement disorders

abnormal activity in the globus pallidus in off-period dystonia (Hashimoto et al) 2001;49:242

decreased serum ceruloplasmin and copper levels in cervical dystonia (Mezaki et al) 2001;49:138 (Letter)

DYT13, a novel primary torsion dystonia locus, maps to chromosome 1p36.13-36.32 in an Italian family with cranial-cervical or upper limb onset (Valente et al) 2001;49:362

familial dyskinesia and facial myokymia (FDFM): a novel movement disorder (Fernandez et al) 2001;49:486

familial dyskinesia and facial myokymia (FDFM): a novel movement disorder (Fernandez et al) 2001;49:486

reduction of Menkes mRNA and copper in leukocytes of patients with primary adult-onset dystonia (Kruse et al) 2001;49:405

risk of tremor and impairment from tremor in relatives of patients with essential tremor: a community-based family study (Louis et al) 2001;49:761

mRNA see RNA, messenger

Multiple sclerosis

Chlamydia pneumoniae-specific humoral immune responses and clinical disease parameters in multiple sclerosis (Krametter et al) 2001;49:135 (Letter) placebo-

controlled clinical trials in multiple sclerosis: ethical considerations (Lublin et al) 2001;49:677

presence of *Chlamydia pneumoniae* DNA in the cerebral spinal fluid is a common phenomenon in a variety of neurological diseases and not restricted to multiple sclerosis (Gieffers et al) 2001;49:585

Multiple sclerosis, diagnosis

anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis (Sastre-Gariga et al) 2001;49:408

Multiple sclerosis, etiology

Chlamydia pneumoniae and multiple sclerosis: innocent bystander or culprit? (Quinn) 2001;49:557 (Editorial)

Multiple sclerosis, imaging

effects of seasons on magnetic resonance imaging measured disease activity in patients with multiple sclerosis (Rovaris et al) 2001;49:415 (Letter)

a longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions (Bitsch et al) 2001;49:793

Multiple sclerosis, pathology

diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis (Johnston et al) 2001;49:650

platelet-derived growth factor-(alpha symbol) receptor-positive oligodendroglia are frequent in multiple sclerosis lesions (Maeda et al) 2001;49:776

Multiple sclerosis, treatment

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on MRI-measured disease activity and burden in patients with relapsing multiple sclerosis (Comi et al) 2001;49:290

placebos on trial (Moreno) 2001;49:558 (Editorial)

prospects for the treatment of multiple sclerosis by raising serum levels of uric acid, a scavenger of peroxynitrite (Koprowski) 2001;49:139 (Letter)

Multiple sclerosis; treatment

The ups and downs of multiple sclerosis therapeutics (Hohlfeld & Wiendl) 2001;49:281 (Editorial)

Multiple sclerosis, treatment

the ups and downs of multiple sclerosis therapy (Hohlfeld and Wiendl) 2001;49:283 (Editorial)

Muscular dystrophy

distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype (Illa et al) 2001;49:130

gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations (Wagner et al) 2001;49:706

when running a stop sign may be a good thing (Karpati) 2001;49:693 (Editorial)

Mutations

abnormal desmin protein in myofibrillar myopathies caused by desmin gene mutations (Li and Dalakas) 2001;49:532

adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening (Bezman et al) 2001;49:512

clinical and pathological features of a parkinsonian syndrome in a family with an ALA53Thr gamma-stnuclein mutation (Spira et al) 2001;49:313

compound heterozygous D90A and D96N SOD1 mutations in a recessive amyotrophic lateral sclerosis family (Hand et al) 2001;49:267

distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype (Illa et al) 2001;49:130

Down's syndrome fibroblasts anticipate the accumulation of specific ageing-related mtDNA mutations (Del Bo et al) 2001;137:138

evidence for digenic inheritance in a family with both febrile convulsions and temporal lobe epilepsy implicating chromosomes 18qter and 1q25-231 (Baulac et al) 2001;49:786

family atypical progressive supranuclear palsy associated with homozygosity for the delN296 mutation in the tau gene (Pastor et al) 2001;49:263

further evidence that neurofilament light chain gene mutations can cause Charcot-Marie-Tooth disease type 2E (De Jonghe et al) 2001;49:245

gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations (Wagner et al) 2001;49:706

germline mutations in the *CCM1* gene, encoding Krit1, cause cerebral cavernous malformations (Lucas et al) 2001;49:529

inherited myoclonus-dystonia syndrome: narrowing the 7q21-q31 locus in German families (Asmus et al) 2001; 49:121

mutations in the complex I *NDUFS2* gene of patients with cardiomyopathy and encephalomyopathy (Loeffen et al) 2001;49:195

novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy (Grabowski et al) 2001;49:697

novel mtDNA mutation in the ND5 subunit of complex I in two MELAS patients (Corona et al) 2001;49:106

novel TRK A (*NTRK1*) mutation associated with hereditary sensory and autonomic neuropathy type V (Houlden et al) 2001;49:521

positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the *Parkin* gene (Hilker et al) 2001;49:367

SCA12 is a rare locus for autosomal dominant cerebellar ataxia: a study of an Indian family (Fujigasaki et al) 2001;49:117

subclinical cerebellar impairment in the common types of migraine: a three-dimensional analysis of reaching movements (Sándor et al) 2001;49:668

SURF1 gene mutation presenting as isolated leukodystrophy (Rahman et al) 2001;49:805

when running a stop sign may be a good thing (Karpati) 2001;49:693 (Editorial)

Myoclonus

lack of activation of human secondary somatosensory cortex in Unverricht-Lundborg type of progressive myoclonus epilepsy (Forss et al) 2001;49:90

Myoclonus-dystonia syndrome

inherited myoclonus-dystonia syndrome: narrowing the 7q21-q31 locus in German families (Asmus et al) 2001; 49:121

Myopathy

abnormal desmin protein in myofibrillar myopathies caused by desmin gene mutations (Li and Dalakas) 2001;49:532

antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia (Lodi et al) 2001;49:590

distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype (Illa et al) 2001;49:130

exercise intolerance in mitochondrial myopathy is not related to lactic acidosis (Vissing et al) 2001;49:672

incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA abnormalities (Darin et al) 2001;49:377

late-onset mitochondrial DNA depletion: DNA copy number, multiple deletions, and compensation (Barthélémy et al) 2001;49:607

mutations in the complex I *NDUFS2* gene of patients with cardiomyopathy and encephalomyopathy (Loeffen et al) 2001;49:195

a novel autosomal dominant distal myopathy with early respiratory failure: clinico-pathologic characteristics and exclusion of linkage to candidate genetic loci (Chinnery et al) 2001;49:443

sequence-selective DNA binding drugs mithramycin A and chromomycin A'd3'D are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons (Chatterjee et al) 2001;49:345

Narcolepsy

hypocretin deficiency in familial symptomatic narcolepsy (Melberg et al) 2001;49:136 (Letter)

NBQX

subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease (Blandini et al) 2001;49:525

Neuroimaging

absence of *N*-acetylaspartate in the human brain: impact on neurospectroscopy? (Martin et al) 2001;49:518

N-acetyl aspartate-a neuronal marker? (Barker) 2001;49:423 (Editorial)

effects of seasons on magnetic resonance imaging measured disease activity in patients with multiple sclerosis (Rovaris et al) 2001;49:415 (Letter)

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on MRI-measured disease activity and burden in patients with relapsing multiple sclerosis (Comi et al) 2001;49:290

irreversible brain creatine deficiency with elevated serum and urine creatine: a creatine transporter defect? (Cecil et al) 2001;49:401

a longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions (Bitsch et al) 2001;49:793

perfusion magnetic resonance abnormalities in patients with sickle cell disease (Kirkham et al) 2001;49:477

postnatal maturation of human GAGA'd3'D receptors measured with positron emission tomography (Chugani et al) 2001;49:618

right lateralized motor cortex activation during volitional blinking (Eimeren et al) 2001;49:813

stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia (Schellinger et al) 2001;49:460

texture analysis of morphological processing of magnetic resonance imaging assist detection of focal cortical dysplasia in extra-temporal partial epilepsy (Bernaconi et al) 2001;49:770

tracking post-stroke recovery with magnetoencephalography (Rossini) 2001;49:136 (Letter)

tracking post-stroke recovery with magnetoencephalography (Rossini) 2001;49:136 (Letter)

Neurological disorders

potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

presence of *Chlamydia pneumoniae* DNA in the cerebral spinal fluid is a common phenomenon in a variety of neurological diseases and not restricted to multiple sclerosis (Gieffers et al) 2001;49:585

Neurons

loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment (Kordower et al) 2001;49:202

potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

selective alterations in glutamate and GAGA receptor subunit mRNA expression in dysplastic neurons and giant cells of cortical tubers (White et al) 2001;49:67

sequence-selective DNA binding drugs mithramycin A and chromomycin A'd3'D are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons (Chatterjee et al) 2001;49:345

superoxide stress identifies neurons at risk in a model of ataxia-telangiectasia (Quick and Dugan) 2001;49:627

Neuropeptides

neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation (Nelson et al) 2001;49:597

Neurotrophins

neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation (Nelson et al) 2001;49:597

Nicotinamide

potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

Nipah virus

treatment of acute Nipah encephalitis with ribavirin (Chong et al) 2001;49:810

Nitric oxide

electrically active axons degenerate when exposed to nitric oxide (Smith et al) 2001;49:470

Nociception

is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache? (Ebersberger et al) 2001;49:7

Nutritional supplements

antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia (Lodi et al) 2001;49:590

potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

Ocular oscillations

ocular oscillations induced by shifts of the direction and depth of visual fixation (Bhidayasiri et al) 2001;49:24

Oligodendroglia

platelet-derived growth factor-(alpha symbol) receptor-positive oligodendroglia are frequent in multiple sclerosis lesions (Maeda et al) 2001;49:776

Oxidative stress

role of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity (Lotharius and O'Malley) 2001;49:79
sequence-selective DNA binding drugs mithramycin A and chromomycin A \backslash D are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons (Chatterjee et al) 2001;49:345
superoxide stress identifies neurons at risk in a model of ataxia-telangiectasia (Quick and Dugan) 2001;49:627

Pain

(alpha symbol)-adrenergic supersensitivity of the sudomotor nerve in complex regional pain syndrome (Ch \backslash mali et al) 2001;49:453
mechanisms and predictors of chronic facial pain in lateral medullary infarction (Fitzek et al) 2001;49:493
a novel TRK A (*NTRK1*) mutation associated with hereditary sensory and autonomic neuropathy type V (Houlden et al) 2001;49:521

Paralysis

sexual arousal and orgasm in women: effects of spinal cord injury (Spiski et al) 2001;49:35
Paraneoplastic antibodies
anti-Yo antibodies and cerebellar degeneration in a man with adenocarcinoma of the esophagus (Sutton et al) 2001;49:253
CRMP-5 neuronal autoantibody: marker for lung cancer and thymoma-related autoimmunity (Yu et al) 2001;49:146
paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy (Antoine et al) 2001;49:214
yet another paraneoplastic antibody (Posner and Dalmau) 2001;49:141 (Editorial)

Paraparesis, spastic

variable phenotype of Alzheimer's disease with spastic paraparesis (Smith et al) 2001;49:125

Parkinson's disease, clinicopathology

clinical and pathological features of a parkinsonian syndrome in a family with an ALA53Thr gamma-synuclein mutation (Spira et al) 2001;49:313
familial amyotrophic lateral sclerosis and parkinsonism-dementia complex of the Kii Peninsula of Japan: clinical and neuropathological study and tau analysis (Kuzuhara et al) 2001;49:501

Parkinson's disease, genetics

no evidence of association between a dopamine transporter gene polymorphism (1215A/G) and Parkinson's disease (Kimura et al) 2001;49:276 (Letter)
Parkinson's disease is not associated with the combined α -synuclein/apolipoprotein E susceptibility genotype (Khan et al) 2001;49:665
positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the *Parkin* gene (Hilker et al) 2001;49:367

Parkinson's disease, pathology

abnormal activity in the globus pallidus in off-period dystonia (Hashimoto et al) 2001;49:242
biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover (Fuente-Fernández et al) 2001;49:298

subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease (Blandini et al) 2001;49:525

Parkinson's disease, treatment

deep brain stimulation for Parkinson's disease (Delong and Wichmann) 2001;49:142 (Editorial)
functional correlates of pallidal stimulation for Parkinson's disease (Fukuda et al) 2001;49:155
the neurochemistry of therapeutics: levodopa pharmacodynamics in Parkinson's disease (Frey) 2001;49:285 (Editorial)

subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease (Blandini et al) 2001;49:525

Peripheral neuropathy

paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy (Antoine et al) 2001;49:214

Peroxisome proliferator-activated receptors

role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease (Heneka et al) 2001;49:276 (Letter)

Pick disease

focal dementia syndromes: in search of the gold standard (Petersen) 2001;49:421 (Editorial)

Placebos

placebos on trial (Moreno) 2001;49:558 (Editorial)

Platelet-derived growth factor-(alpha symbol) receptor
platelet-derived growth factor-(alpha symbol) receptor-positive oligodendroglia are frequent in multiple sclerosis lesions (Maeda et al) 2001;49:776

Positron emission tomography

postnatal maturation of human GAGA \backslash dA \backslash D receptors measured with positron emission tomography (Chugani et al) 2001;49:618

right lateralized motor cortex activation during volitional blinking (Eimeren et al) 2001;49:813

Progressive multifocal leukoencephalopathy

cellular and humoral immune response in progressive multifocal leukoencephalopathy (Weber et al) 2001;49:636

Progressive supranuclear palsy

familial atypical progressive supranuclear palsy associated with homozygosity for the delN296 mutation in the tau gene (Pastor et al) 2001;49:263

Propofol

propofol in subanesthetic doses terminates status epilepticus in a rodent model (Holtkamp et al) 2001;49:260

Reactive oxygen species

superoxide stress identifies neurons at risk in a model of ataxia-telangiectasia (Quick and Dugan) 2001;49:627

Receptors, adenosine

adenosine A \backslash D \backslash D \backslash D receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage (Mayne et al) 2001;49:727

Receptors, GABA \backslash A

postnatal maturation of human GAGA \backslash dA \backslash D receptors measured with positron emission tomography (Chugani et al) 2001;49:618

Receptors, peroxisome proliferator-activated role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease (Heneka et al) 2001;49:276 (Letter)

Receptors, platelet-derived growth factor-(alpha symbol)
platelet-derived growth factor- α receptor-positive oligodendroglia are frequent in multiple sclerosis lesions (Maeda et al) 2001;49:776

Restless legs syndrome

intermediate CAG repeat lengths (53,54) for MJD/SCA3 are associated with an abnormal phenotype (Alfen et al) 2001;49:797

Retinitis

HSV-induced retinitis following herpes simplex encephalitis: indications for brain-to-eye transmission of HSV-1 (Maertzdorf et al) 2001;49:104

Ribavirin

treatment of acute Nipah encephalitis with ribavirin (Chong et al) 2001;49:810

Riboflavin

potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

Riluzole

effects of riluzole on cortical excitability in patients with amyotrophic lateral sclerosis (Stefan et al) 2001;49:536

RNA, messenger

intron 7 retention and exon 9 skipping EAAT2 mRNA variants are not associated with amyotrophic lateral sclerosis (Flowers et al) 2001;49:643

selective alterations in glutamate and GAGA receptor subunit mRNA expression in dysplastic neurons and giant cells of cortical tubers (White et al) 2001;49:67

Seizures; see also Epilepsy

evidence for digenic inheritance in a family with both febrile convulsions and temporal lobe epilepsy implicating chromosomes 18qter and 1q25-q31 (Baulac et al) 2001;49:786

foal cooling rapidly terminates experimental neocortical seizures (Yang & Rothman) 2001;49:721

how does ACTH work against infantile spasms? Bedside to bench (Snead) 2001;49:288 (Editorial)

how long do new-onset seizures in children last? (Shinnar et al) 2001;49:659

propofol in subanesthetic doses terminates status epilepticus in a rodent model (Holtkamp et al) 2001;49:260

Sensory neuropathy

a novel TRK A (*NTRK1*) mutation associated with hereditary sensory and autonomic neuropathy type V (Houlden et al) 2001;49:521

Sexual function

sexual arousal and orgasm in women: effects of spinal cord injury (Spiski et al) 2001;49:35

Sickle cell disease

improved cerebrovascular patency following therapy in patients with sickle cell disease: initial results in 4 patients who received HLA-identical hematopoietic stem cell allografts (Steen et al) 2001;49:222

perfusion magnetic resonance abnormalities in patients with sickle cell disease (Kirkham et al) 2001;49:477

Somatosensory cortex

lack of activation of human secondary somatosensory cortex in Unverricht-Lundborg type of progressive myoclonus epilepsy (Forss et al) 2001;49:90

Spasticity

variable phenotype of Alzheimer's disease with spastic paraparesis (Smith et al) 2001;49:125

Spinal cord injury

sexual arousal and orgasm in women: effects of spinal cord injury (Spiski et al) 2001;49:35

Spinocerebellar ataxia

intermediate CAG repeat lengths (53,54) for MJD/SCA3 are associated with an abnormal phenotype (Alfen et al) 2001;49:797

Statins

plasma levels of amyloid β proteins did not differ between subjects taking statins and those not taking statins (Tokuda et al) 2001;49:546 (Letter)

Status epilepticus

propofol in subanesthetic doses terminates status epilepticus in a rodent model (Holtkamp et al) 2001;49:260

Stem cell graft

improved cerebrovascular patency following therapy in patients with sickle cell disease: initial results in 4 patients who received HLA-identical hematopoietic stem cell allografts (Steen et al) 2001;49:222

Stroke

tracking post-stroke recovery with magnetoencephalography (Rossini) 2001;49:136 (Letter)

Substantia nigra

subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease (Blandini et al) 2001;49:525

Sudomotor nerve

α -adrenergic supersensitivity of the sudomotor nerve in complex regional pain syndrome (Chémali et al) 2001;49:453

Superoxide stress

superoxide stress identifies neurons at risk in a model of ataxia-telangiectasia (Quick and Dugan) 2001;49:627

α -Synuclein

Parkinson's disease is not associated with the combined α -synuclein/apolipoprotein E susceptibility genotype (Khan et al) 2001;49:665

Tat protein

HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors (Johnston et al) 2001;49:230

Tau protein

the case of the missing tau, or, why didn't the mRNA bark? (Bird and Schellenberg) 2001;49:144 (Editorial)

familial amyotrophic lateral sclerosis and parkinsonism-dementia complex of the Kii Peninsula of Japan: clinical and neuropathological study and tau analysis (Kuzuhara et al) 2001;49:501

familial atypical progressive supranuclear palsy associated with homozygosity for the delN296 mutation in the tau gene (Pastor et al) 2001;49:263

honorable compromise regarding amyloid in Alzheimer's disease (Terry) 2001;49:684 (Letter)

the hound that did not bark in the night (Schaumburg) 2001;49:817 (Letter)

loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia (Zhukareva et al) 2001;49:165

a novel autosomal dominant distal myopathy with early respiratory failure: clinico-pathologic characteristics and exclusion of linkage to candidate genetic loci (Chinnery et al) 2001;49:443

tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231 (Hampel et al) 2001;49:545 (Letter)

T cells

are transfected cells essential for measuring cytotoxic T cells in paraneoplastic cerebellar degeneration? (Tanaka and Tanaka) 2001;49:686 (Letter)

Temporal lobe

patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease (Chan et al) 2001;49:433

Thymoma

CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity (Yu et al) 2001; 49:146

Tic disorder

children with comorbid attention-deficit-hyperactivity disorder and tic disorder: evidence for additive inhibitory deficits within the motor system (Moll et al) 2001;49: 393

Tissue plasminogen activator

apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke (Broderick et al) 2001;49:736

Tomography, emission computed

positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the *Parkin* gene (Hilker et al) 2001;49:367

Tremor

risk of tremor and impairment from tremor in relatives of patients with essential tremor: a community-based family study (Louis et al) 2001;49:761

Tuberous sclerosis

selective alterations in glutamate and GAGA receptor subunit mRNA expression in dysplastic neurons and giant cells of cortical tubers (White et al) 2001;49:67

Tumor markers

CRMP-5 neuronal autoantibody: marker for lung cancer and thymoma-related autoimmunity (Yu et al) 2001; 49:146

Twins

causes of epilepsies: insights from discordant monozygotic twins (Briellmann et al) 2001;49:45

Tyrosine phosphate

laforin is a cell membrane and endoplasmic reticulum-associated protein tyrosine phosphatase (Minassian et al) 2001;49:271

Ullrich's disease

collagen VI deficiency in Ullrich's disease (Higuchi et al) 2001;49:544 (Letter)

Unverricht-Lundborg disease

lack of activation of human secondary somatosensory cortex in Unverricht-Lundborg type of progressive myoclonus epilepsy (Forss et al) 2001;49:90

Visual fields

care should be taken in interpretation of visual field tests in children (Vanhalatalo) 2001;49:277 (Letter)

Vitamins, antioxidant

antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia (Lodi et al) 2001;49:590

potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

X-linked adrenoleukodystrophy

evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy (Van Geel et al) 2001; 49:186

